
Supriya Peshin/X
May 30, 2025, 14:45
Supriya Peshin: FDA Approved Retifanlimab Combination for 1st Line Treatment of Advanced SCAC
Supriya Peshin, Visiting Resident in Hematology and Oncology at MD Anderson Cancer Center, shared a post on X:
“Learned something new today in GI Oncclinic MD Anderson Cancer Center: FDA approved retifanlimab +carboplatin/paclitaxel for first-line treatment of advanced SCAC major step forward in care for Anal cancer.”
Read Full Blog on FDA.
Read More on OncoDaily’s special article: “FDA Approves Retifanlimab-dlwr with Chemotherapy and as Monotherapy for Advanced Squamous Cell Carcinoma of the Anal Canal”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 30, 2025, 14:31
May 30, 2025, 13:19
May 30, 2025, 12:53
May 30, 2025, 12:46
May 30, 2025, 12:32